CRBU Stock Analysis: Caribou Biosciences | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 181m USD | 12M Return: 30.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.55M
Qual. Beats: 0
Rev. Trend: -70.2%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 4.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Caribou Biosciences, Inc. (NASDAQ: CRBU) is a clinical-stage biopharmaceutical company headquartered in Berkeley, California, focused on developing allogeneic cell therapies using its proprietary CRISPR hybrid RNA-DNA genome-editing platform. Founded in 2011, the company went public in July 2021 and currently operates as a micro-cap within the Health Care / Biotechnology sector.
The companys clinical pipeline is led by two Phase 1 allogeneic CAR-T cell therapy candidates: Vispacabtagene Regedleucel, an anti-CD19 therapy targeting relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an anti-BCMA therapy for relapsed or refractory multiple myeloma. Both programs are being evaluated in early-stage clinical trials.
Caribous business model centers on allogeneic (off-the-shelf) cell therapies, which are manufactured from healthy donor cells rather than a patients own cells, in contrast to autologous approaches. The company leverages CRISPR-based gene editing to engineer these cell therapies with the aim of producing scalable, standardized treatments for hematologic cancers and other diseases.
- CB-011 Phase 1 multiple myeloma data readout approaches
- Vispacabtagene Regedleucel Phase 1 lymphoma update due
- Cash burn raises dilution risk on micro-cap balance sheet
| Net Income: -133.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.68 > 0.02 and ΔFCF/TA -16.21 > 1.0 |
| NWC/Revenue: 916.8% < 20% (prev 1.90k%; Δ -987.1% < -1%) |
| CFO/TA -0.68 > 3% & CFO -101.3m > Net Income -133.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.22 > 1.5 & < 3 |
| Outstanding Shares: last quarter (95.9m) vs 12m ago 3.43% < -2% |
| Gross Margin: 70.90% > 18% (prev -528.0%; Δ 598.9% > 0.5%) |
| Asset Turnover: 5.30% > 50% (prev 3.62%; Δ 1.68% > 0%) |
| Interest Coverage Ratio: -6.16 > 6 (EBIT TTM -115.1m / Interest Expense TTM 18.7m) |
| A: 0.69 (Total Current Assets 122.4m - Total Current Liabilities 19.7m) / Total Assets 149.0m |
| B: -4.17 (Retained Earnings -621.6m / Total Assets 149.0m) |
| C: -0.54 (EBIT TTM -115.1m / Avg Total Assets 211.3m) |
| D: 2.17 (Book Value of Equity 102.0m / Total Liabilities 47.0m) |
| Altman-Z'' = -10.46 = D |
| DSRI: 0.76 (Receivables 2.36m/2.74m, Revenue 11.2m/9.92m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.32 (AQ_t 0.02 / AQ_t-1 0.07) |
| SGI: 1.13 (Revenue 11.2m / 9.92m) |
| TATA: -0.21 (NI -133.2m - CFO -101.3m) / TA 149.0m) |
| Beneish M = -3.56 (Cap -4..+1) = AAA |
As of July 06, 2026, the stock is trading at USD 1.82 with a total of 1,868,938 shares traded. Over the past week, the price has changed by +15.92%, over one month by -5.21%, over three months by -6.67% and over the past year by +30.94%.
Current recommended Stop Loss: 1.60 (which is 12.1% or 1.7 ATR below the current price).
Caribou Biosciences has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy CRBU.
- StrongBuy: 5
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 12 | 559.3% |
P/S = 16.1125
P/B = 1.711
Revenue TTM = 11.2m USD
EBIT TTM = -115.1m USD
EBITDA TTM = -112.0m USD
Long Term Debt = 25.7m USD (estimated: total debt 26.9m - short term 1.29m)
Short Term Debt = 1.29m USD (from shortTermDebt, last quarter)
Debt = 26.9m USD (from shortLongTermDebtTotal, last quarter) (leases 26.9m already included)
Net Debt = -90.7m USD (calculated: Debt 26.9m - CCE 117.6m)
Enterprise Value = 89.8m USD (180.5m + Debt 26.9m - CCE 117.6m)
Interest Coverage Ratio = -6.16 (Ebit TTM -115.1m / Interest Expense TTM 18.7m)
EV/FCF = -0.88x (Enterprise Value 89.8m / FCF TTM -101.6m)
FCF Yield = -113.1% (FCF TTM -101.6m / Enterprise Value 89.8m)
FCF Margin = -907.3% (FCF TTM -101.6m / Revenue TTM 11.2m)
Net Margin = -1.19k% (Net Income TTM -133.2m / Revenue TTM 11.2m)
Gross Margin = 70.90% ((Revenue TTM 11.2m - Cost of Revenue TTM 3.26m) / Revenue TTM)
Gross Margin QoQ = 72.92% (prev 82.69%)
Tobins Q-Ratio = 0.60 (Enterprise Value 89.8m / Total Assets 149.0m)
Interest Expense / Debt = 69.29% (Interest Expense 18.7m / Debt 26.9m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -90.9m (EBIT -115.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.22 (Total Current Assets 122.4m / Total Current Liabilities 19.7m)
Debt / Equity = 0.26 (Debt 26.9m / totalStockholderEquity, last quarter 102.0m)
Debt / EBITDA = 0.81 (negative EBITDA) (Net Debt -90.7m / EBITDA -112.0m)
Debt / FCF = 0.89 (negative FCF - burning cash) (Net Debt -90.7m / FCF TTM -101.6m)
Total Stockholder Equity = 133.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -63.04% (Net Income -133.2m / Total Assets 149.0m)
RoE = -100.1% (Net Income TTM -133.2m / Total Stockholder Equity 133.0m)
RoCE = -72.53% (EBIT -115.1m / Capital Employed (Equity 133.0m + L.T.Debt 25.7m))
RoIC = -69.92% (negative operating profit) (NOPAT -90.9m / Invested Capital 130.1m)
WACC = 12.37% (E(180.5m)/V(207.5m) * Re(14.22%) + (debt cost/tax rate unavailable))
Discount Rate = 14.22% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 89.44 | Cagr: 12.26%
[DCF] Fair Price = unknown (Cash Flow -101.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.81 | # QB: 0
Revenue Correlation: -70.18 | Revenue CAGR: -36.31% | SUE: 0.37 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.31 | Chg30d=+2.63% | Revisions=+0% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.32 | Chg30d=+0.00% | Revisions=+0% | Analysts=3
EPS current Year (2026-12-31): EPS=-1.25 | Chg30d=+0.66% | Revisions=-25% | GrowthEPS=+15.1% | GrowthRev=+130.0%
EPS next Year (2027-12-31): EPS=-1.40 | Chg30d=+6.67% | Revisions=-25% | GrowthEPS=-12.3% | GrowthRev=+17.2%
[Analyst] Revisions Ratio: -40% (up=0, down=2)